Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors

Autor: Willeke R. Naaktgeboren, Wim G. Groen, Judy N. Jacobse, Lars C. Steggink, Annemiek M.E. Walenkamp, Wim H. van Harten, Martijn M. Stuiver, Neil K. Aaronson, Berthe M.P. Aleman, Peter van der Meer, Michael Schaapveld, Gabe S. Sonke, Jourik A. Gietema, Flora E. van Leeuwen, Anne M. May

Publikováno v: JACC: CardioOncology. 4:183-191

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1d2fb591b7cc7f973715f3e425cac193
https://doi.org/10.1016/j.jaccao.2022.02.007

Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors

Autor: Annemiek, van Ommen-Nijhof, Judy N, Jacobse, Lars C, Steggink, Joop D, Lefrandt, Jourik A, Gietema, Flora E, van Leeuwen, Michael, Schaapveld, Gabe S, Sonke

Publikováno v: Breast cancer research and treatment. 196(3)

Aromatase inhibitors (AIs) are an important component of the adjuvant treatment of hormone receptor positive breast cancer (BC) but concerns regarding their cardiovascular safety remain. In this cross-sectional study nested in a breast cancer cohort,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::24167c2ec9407bc39a4588da19d4023f
https://pubmed.ncbi.nlm.nih.gov/36181605

Insulin-like factor 3, luteinizing hormone and testosterone in testicular cancer patients

Autor: Jourik A. Gietema, Janine Nuver, Lars C Steggink, Coby Meijer, A. P. van Beek, Joop D. Lefrandt, Sjoukje F. Oosting, R. J. van Ginkel, Sjoukje Lubberts, I. J. de Jong, Hink Boer

Publikováno v: Andrology, 7(4), 441-448. John Wiley & Sons Inc.
Andrology, 7(4), 441-448. Wiley

BACKGROUND: Primary hypogonadism (low testosterone and high luteinizing hormone, LH) is present in approximately 20% of testicular cancer (TC) survivors after orchidectomy with or without chemotherapy.OBJECTIVES: We investigated insulin-like factor 3

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::223c0ce44d3be29bc5c5572b865ff315
https://doi.org/10.1111/andr.12581

Predictive value of ectopic HORMAD1 tumor expression for high-dose platinum-based chemotherapy benefit in patients with high-risk HER2-negative breast cancer

Autor: Leonora De Boo, Jelmar Quist, Mark Opdam, Katarzyna Jozwiak, Patrycja Gazinska, Dennis Peters, Hugo M. Horlings, Tessa Gerjanne Steenbruggen, Lars C. Steggink, Elisabeth De Vries, Gabe S. Sonke, Jourik A. Gietema, Andrew Tutt, Marleen Kok, Anita Grigoriadis, Sabine C. Linn

Publikováno v: Journal of Clinical Oncology. 40:541-541

541 Background: The meiotic DNA break regulator HORMAD1 is aberrantly expressed in many cancers and is associated with increased genomic instability. The susceptibility of HORMAD1 expressing tumors to agents targeting DNA damage repair (DDR) pathways

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dff02a496e728e041bd36c91396fae79
https://doi.org/10.1200/jco.2022.40.16_suppl.541

High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes 20-Year Follow-up of a Phase 3 Randomized Clinical Trial

Autor: Caroline M. Seynaeve, Elsken van der Wall, Elisabeth G.E. de Vries, Wim M. Smit, Jacobus J M van der Hoeven, Vivianne C. G. Tjan-Heijnen, Judith R. Kroep, Harm van Tinteren, Flora E. van Leeuwen, Judy N. Jacobse, Jourik A. Gietema, Carolien P. Schröder, Lars C Steggink, Gabe S. Sonke, Maartje J. Hooning, Tessa G Steenbruggen, Sabine C. Linn, Michael Schaapveld, Inge R Konings, Agnes Jager, Adriaan Bins

Publikováno v: Jama Oncology, 6, 4, pp. 528-534
JAMA Oncology, 6(4), 528-534. American Medical Association
Steenbruggen, T G, Steggink, L C, Seynaeve, C M, Van Der Hoeven, J J M, Hooning, M J, Jager, A, Konings, I R, Kroep, J R, Smit, W M, Tjan-Heijnen, V C G, Van Der Wall, E, Bins, A D, Linn, S C, Schaapveld, M, Jacobse, J N, Van Leeuwen, F E, Schröder, C P, Van Tinteren, H, De Vries, E G E, Sonke, G S & Gietema, J A 2020, ' High-Dose Chemotherapy with Hematopoietic Stem Cell Transplant in Patients with High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes : 20-Year Follow-up of a Phase 3 Randomized Clinical Trial ', JAMA Oncology, vol. 6, no. 4, pp. 528-534 . https://doi.org/10.1001/jamaoncol.2019.6276
JAMA oncology, 6(4), 528-534. American Medical Association
JAMA Oncology, 6(4), 528-534. AMER MEDICAL ASSOC
JAMA Oncol
Jama Oncology, 6, 528-534

Importance: Trials of adjuvant high-dose chemotherapy (HDCT) have failed to show a survival benefit in unselected patients with breast cancer, but long-term follow-up is lacking. Objective: To determine 20-year efficacy and safety outcomes of a large

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc75b5fa1a0ce92730e37111e77ccec6
https://hdl.handle.net/2066/218567